Movement Disorders

Samantha M. Meadows, Melissa M. Conti, Libby Gross, Nicole E. Chambers, Yarden Avnor, Corinne Y. Ostock, Kathryn Lanza, Christopher Bishop November 29, 2018

ABSTRACT

Background: The serotonergic system is a well‐established modulator of l‐dopa‐induced dyskinesia. To date, targeting serotonin transporters or serotonin receptor subtype 1A (5‐HT1A) reduces l‐dopa‐induced dyskinesia in animal models; however, these strategies have failed to translate clinically.… Read More...

Asha Kishore, Ashwin Ashok Kumar Sreelatha, Marc Sturm, Felix von‐Zweydorf, Lasse Pihlstrøm, Francesco Raimondi, Rob Russell, Peter Lichtner, Moinak Banerjee, Syam Krishnan, Roopa Rajan, Divya Kalikavil Puthenveedu, Sun Ju Chung, International Parkinson's Disease Genomics Consortium (IPDGC), Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson's Disease (COURAGE‐PD), Peter Bauer, Olaf Riess, Christian Johannes Gloeckner, Rejko Kruger, Thomas Gasser, Manu Sharma November 29, 2018

ABSTRACT

Background

Genetic variability in LRRK2 has been unequivocally established as a major risk factor for familial and sporadic forms of PD in ethnically diverse populations.

Objectives

To resolve the role of LRRK2 in the Indian population.

Methods

We performed targeted resequencing of the LRRK2 locus in 288 cases and 298 controls and resolved the haplotypic structure of LRRK2 in a combined cohort of 800 cases and 402 controls in the Indian population.… Read More...

Shi‐shuang Cui, Juan‐Juan Du, Shi‐Hua Liu, Jie Meng, Yi‐Qi Lin, Gen Li, Yi‐Xi He, Ping‐Chen Zhang, Shengdi Chen, Gang Wang November 29, 2018

Abstract

Objective: Lymphocyte activation gene‐3 (LAG‐3) could mediate pathological α‐synuclein transmission in neurodegeneration and may be involved in the pathogenesis of Parkinson’s disease (PD). The aim of the present study was to explore soluble LAG‐3 (sLAG‐3) as a potential diagnostic biomarker for PD.… Read More...

Sophie B. Sébille, Anne‐Sophie Rolland, Matthieu Faillot, Fernando Perez‐Garcia, Antoine Colomb‐Clerc, Brian Lau, Sylvie Dumas, Sara Fernandez Vidal, Marie‐Laure Welter, Chantal Francois, Eric Bardinet, Carine Karachi November 29, 2018

ABSTRACT

Background: Deep brain stimulation of the pedunculopontine nucleus has been performed to treat dopamine‐resistant gait and balance disorders in patients with degenerative diseases. The outcomes, however, are variable, which may be the result of the lack of a well‐defined anatomical target.… Read More...

Friederike Irmen, Andreas Horn, David Meder, Wolf‐Julian Neumann, Philip Plettig, Gerd‐Helge Schneider, Hartwig Roman Siebner, Andrea A. Kühn November 29, 2018

Abstract

Background

STN‐DBS effectively treats motor symptoms of advanced PD. Nonmotor cognitive symptoms, such as impaired impulse control or decision making, may either improve or worsen with DBS. A potential mediating factor of DBS‐induced modulation of cognition is the electrode position within the STN with regard to functional subareas of parallel motor, cognitive, and affective basal ganglia loops.… Read More...

Andoird App
Loading...